close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.430 -0.010 (-0.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings For Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges ↗
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... 
Via Benzinga
News headline image
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Allogene Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names ↗
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence. 
Via InvestorPlace
News headline image
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation ↗
 
Via Benzinga
Topics ETFs
News headline image
3 Meme Stocks to Sell and Replace With Meme Coins ↗
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs. 
Via InvestorPlace
News headline image
Allogene Therapeutics Announces Q2 Investor Conference Participation
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today